Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:DNTH NASDAQ:INDV NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$54.32+3.6%$52.34$34.87▼$78.48$5.22B1.741.87 million shs336,422 shsDNTHDianthus Therapeutics$86.76+1.5%$81.01$16.64▼$96.50$4.76B1.18927,332 shs59,093 shsINDVIndivior$39.08-1.3%$32.24$10.63▼$41.00$4.77B0.92.36 million shs137,124 shsOLMAOlema Pharmaceuticals$15.00-0.8%$16.58$3.89▼$36.26$1.31B2.051.42 million shs75,121 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-4.83%+0.15%+5.47%+7.55%+52.98%DNTHDianthus Therapeutics-5.47%-2.65%-0.85%+68.41%+327.99%INDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%OLMAOlema Pharmaceuticals-0.39%+5.00%-0.79%-40.34%+226.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$54.32+3.6%$52.34$34.87▼$78.48$5.22B1.741.87 million shs336,422 shsDNTHDianthus Therapeutics$86.76+1.5%$81.01$16.64▼$96.50$4.76B1.18927,332 shs59,093 shsINDVIndivior$39.08-1.3%$32.24$10.63▼$41.00$4.77B0.92.36 million shs137,124 shsOLMAOlema Pharmaceuticals$15.00-0.8%$16.58$3.89▼$36.26$1.31B2.051.42 million shs75,121 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics-4.83%+0.15%+5.47%+7.55%+52.98%DNTHDianthus Therapeutics-5.47%-2.65%-0.85%+68.41%+327.99%INDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%OLMAOlema Pharmaceuticals-0.39%+5.00%-0.79%-40.34%+226.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.56Moderate Buy$65.9421.39% UpsideDNTHDianthus Therapeutics 3.00Buy$117.8235.80% UpsideINDVIndivior 3.00Buy$39.330.66% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.40195.92% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, CRSP, DNTH, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/6/2026DNTHDianthus Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$103.00 ➝ $105.004/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026DNTHDianthus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$98.004/8/2026DNTHDianthus Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/27/2026OLMAOlema Pharmaceuticals Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/25/2026CRSPCRISPR Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/19/2026DNTHDianthus Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$135.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$1M5,239.11N/AN/A$18.81 per share2.89DNTHDianthus Therapeutics$1.34M3,549.98N/AN/A$11.41 per share7.60INDVIndivior$1.24B3.85$2.62 per share14.93($1.18) per share-33.12OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%5/11/2026 (Estimated)DNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-38.79%-36.32%5/11/2026 (Estimated)INDVIndivior$210M$1.9520.0610.62N/A19.44%-219.26%29.40%N/AOLMAOlema Pharmaceuticals-$162.45M-$1.86N/AN/AN/AN/A-42.95%-38.78%5/12/2026 (Estimated)Latest OLMA, CRSP, DNTH, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52N/AN/AN/AN/AN/A5/11/2026Q1 2026DNTHDianthus Therapeutics-$1.1029-$0.85+$0.2529-$0.85$0.40 million$0.46 million5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9713.32DNTHDianthus TherapeuticsN/A13.3213.32INDVIndiviorN/A0.860.66OLMAOlema Pharmaceuticals0.019.959.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%DNTHDianthus Therapeutics47.53%INDVIndivior60.33%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%DNTHDianthus Therapeutics3.02%INDVIndivior0.74%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableDNTHDianthus Therapeutics8054.67 million52.81 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableOLMAOlema Pharmaceuticals7087.35 million73.06 millionOptionableOLMA, CRSP, DNTH, and INDV HeadlinesRecent News About These CompaniesPier Capital LLC Decreases Position in Olema Pharmaceuticals, Inc. $OLMA4 hours ago | marketbeat.comOlema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on TuesdayMay 5 at 1:31 PM | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comJennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comPictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMAMay 2, 2026 | marketbeat.comOlema Pharmaceuticals Adds Veteran Director to Support GrowthApril 29, 2026 | tipranks.comOlema Oncology Appoints Prakash Raman, Ph.D., to Board of DirectorsApril 29, 2026 | globenewswire.comWall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"April 27, 2026 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 22, 2026 | marketbeat.comOlema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comOlema Pharmaceuticals (NASDAQ:OLMA) Downgraded to "Strong Sell" Rating by Wall Street ZenApril 19, 2026 | marketbeat.comOlema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual MeetingApril 18, 2026 | theglobeandmail.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest UpdateApril 14, 2026 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Raised to "Sell" at Wall Street ZenApril 11, 2026 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Trading 7.7% Higher - Here's What HappenedApril 9, 2026 | marketbeat.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | globenewswire.comJim Cramer on Olema Pharmaceuticals: “Too Risky for Me”March 24, 2026 | msn.comOlema Shelf Registration Raises Questions On Dilution And Funding FlexibilityMarch 23, 2026 | finance.yahoo.comOlema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?March 22, 2026 | fool.comOlema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMarch 18, 2026 | zacks.comBiotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchMarch 18, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026OLMA, CRSP, DNTH, and INDV Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$54.32 +1.90 (+3.62%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Dianthus Therapeutics NASDAQ:DNTH$86.76 +1.29 (+1.51%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Indivior NASDAQ:INDV$39.08 -0.52 (-1.32%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Olema Pharmaceuticals NASDAQ:OLMA$15.00 -0.13 (-0.83%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
